Ultragenyx: Q3 2026 revenue at $173 million, expense cuts and 2027 profitability reaffirmed
FROM THE WIRE · GLOBENEWSWIRE.COM
Third quarter total revenue of $173 million, CRYSVITA® revenue of $109 million and DOJOLVI® revenue of $30 million GENGLYCOS™ and FAYUVI™ BLAs approved by FDA in the third quarter Two Priority Review Vouchers (PRVs) under agreement for combined sales price of $413 million…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishThe cost-reduction plan and reaffirmed 2027 profitability can support investor confidence in a mid-sized biopharma company.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Total revenue for the third quarter was $173 million.
- 02CRYSVITA revenue was $109 million and DOJOLVI revenue was $30 million.
- 03The company expects at least a 50% reduction in 2027 R&D expenses versus 2025.
- 04Two Priority Review Vouchers are under agreement for a combined sales price of $413 million.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets